These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10674051)

  • 1. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
    Vegter S; Perna A; Hiddema W; Ruggenenti P; Remuzzi G; Navis G; Postma MJ
    Pharmacogenet Genomics; 2009 Sep; 19(9):695-703. PubMed ID: 19696696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.
    Costa-Scharplatz M; van Asselt AD; Bachmann LM; Kessels AG; Severens JL
    Pharmacogenet Genomics; 2007 May; 17(5):359-68. PubMed ID: 17429318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should all Pima Indians with type 2 diabetes mellitus be prescribed routine angiotensin-converting enzyme inhibition therapy to prevent renal failure?
    Kiberd BA; Jindal KK
    Mayo Clin Proc; 1999 Jun; 74(6):559-64. PubMed ID: 10377929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
    Adarkwah CC; Gandjour A
    Int J Technol Assess Health Care; 2010 Jan; 26(1):62-70. PubMed ID: 20059782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.
    Campbell HM; Boardman KD; Dodd MA; Raisch DW
    Ann Pharmacother; 2007 Jul; 41(7):1101-10. PubMed ID: 17609233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient compliance with drug therapy for diabetic nephropathy.
    Hughes D; Manns B
    CMAJ; 2000 May; 162(11):1553-4. PubMed ID: 10862223
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
    Swislocki AL; Siegel D
    Am J Manag Care; 2001 Mar; 7(3):283-95. PubMed ID: 11258145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease - a Dutch perspective.
    Adarkwah CC; Gandjour A; Akkerman M; Evers S
    Kidney Blood Press Res; 2013; 37(2-3):168-80. PubMed ID: 23689440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective.
    Stafylas PC; Sarafidis PA; Lasaridis AN; Tsakni E; Niakas DA; Dombros NV; Grekas DM; Bakris GL
    J Nephrol; 2007; 20(6):703-15. PubMed ID: 18046673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
    Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
    Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P
    Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for proteinuria in US adults: a cost-effectiveness analysis.
    Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
    JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of angiotensin receptor blockers in patients with type 2 diabetes mellitus and nephropathy in Israel].
    Berar-Yanay N; Leshno M; Hertzeanu L; Weintrob N
    Harefuah; 2008 Mar; 147(3):211-5, 278. PubMed ID: 18488861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.